[go: up one dir, main page]

NO20014485D0 - Nye forbindelser og sammensetninger som proteaseinhibitorer - Google Patents

Nye forbindelser og sammensetninger som proteaseinhibitorer

Info

Publication number
NO20014485D0
NO20014485D0 NO20014485A NO20014485A NO20014485D0 NO 20014485 D0 NO20014485 D0 NO 20014485D0 NO 20014485 A NO20014485 A NO 20014485A NO 20014485 A NO20014485 A NO 20014485A NO 20014485 D0 NO20014485 D0 NO 20014485D0
Authority
NO
Norway
Prior art keywords
protease inhibitors
compositions
new compounds
oxides
novel
Prior art date
Application number
NO20014485A
Other languages
English (en)
Other versions
NO20014485L (no
Inventor
Clifford M Bryant
Barry A Bunin
Erica A Kraynack
John W Patterson
Original Assignee
Axys Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axys Pharm Inc filed Critical Axys Pharm Inc
Publication of NO20014485D0 publication Critical patent/NO20014485D0/no
Publication of NO20014485L publication Critical patent/NO20014485L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/24—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the same saturated acyclic carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/24—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the same saturated acyclic carbon skeleton
    • C07C255/29—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the same saturated acyclic carbon skeleton containing cyano groups and acylated amino groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
    • C07C255/60—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton at least one of the singly-bound nitrogen atoms being acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
    • C07C275/20—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
    • C07C275/24—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/03—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C311/06—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/09—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton the carbon skeleton being further substituted by at least two halogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C07C317/48—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C317/50—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/62—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/06—Preparation of indole from coal-tar
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/26—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an acyl radical attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D233/26—Radicals substituted by carbon atoms having three bonds to hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/215—Radicals derived from nitrogen analogues of carbonic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20014485A 1999-03-15 2001-09-14 Nye forbindelser og sammensetninger som proteaseinhibitorer NO20014485L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12442099P 1999-03-15 1999-03-15
PCT/US2000/006747 WO2000055125A2 (en) 1999-03-15 2000-03-15 N-cyanomethyl amides as protease inhibitors

Publications (2)

Publication Number Publication Date
NO20014485D0 true NO20014485D0 (no) 2001-09-14
NO20014485L NO20014485L (no) 2001-11-05

Family

ID=22414780

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20014485A NO20014485L (no) 1999-03-15 2001-09-14 Nye forbindelser og sammensetninger som proteaseinhibitorer
NO20014484A NO20014484L (no) 1999-03-15 2001-09-14 Nye forbindelser og sammensetninger som proteaseinhibitorer

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20014484A NO20014484L (no) 1999-03-15 2001-09-14 Nye forbindelser og sammensetninger som proteaseinhibitorer

Country Status (32)

Country Link
US (7) US6476026B1 (no)
EP (2) EP1161415B1 (no)
JP (2) JP2002539192A (no)
KR (2) KR100688740B1 (no)
CN (2) CN1362947A (no)
AT (2) ATE259782T1 (no)
AU (2) AU774827B2 (no)
BG (2) BG106003A (no)
BR (2) BR0009042A (no)
CA (2) CA2368122A1 (no)
CZ (2) CZ20013248A3 (no)
DE (2) DE60008369T2 (no)
DK (1) DK1178958T3 (no)
EA (2) EA200100972A1 (no)
EE (2) EE04911B1 (no)
ES (2) ES2215626T3 (no)
HK (2) HK1039108A1 (no)
HR (2) HRP20010737A2 (no)
HU (2) HUP0200503A3 (no)
IL (3) IL145430A0 (no)
IS (1) IS6069A (no)
NO (2) NO20014485L (no)
NZ (1) NZ514234A (no)
PL (2) PL350453A1 (no)
PT (1) PT1178958E (no)
SK (2) SK12892001A3 (no)
TR (3) TR200201874T2 (no)
TW (1) TWI290132B (no)
UA (1) UA76088C2 (no)
WO (2) WO2000055125A2 (no)
YU (1) YU66101A (no)
ZA (2) ZA200107495B (no)

Families Citing this family (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9723407D0 (en) 1997-11-05 1998-01-07 Ciba Geigy Ag Organic compounds
IL145430A0 (en) * 1999-03-15 2002-06-30 Axys Pharm Inc N-cyanomethyl amides, processes for the preparation thereof and pharmaceutical compositions containing the same
CN100410250C (zh) * 1999-09-13 2008-08-13 贝林格尔·英格海姆药物公司 用作半胱氨酸蛋白酶的可逆抑制剂的螺旋杂环化合物
US6420364B1 (en) 1999-09-13 2002-07-16 Boehringer Ingelheim Pharmaceuticals, Inc. Compound useful as reversible inhibitors of cysteine proteases
EP1212302A1 (en) * 1999-09-16 2002-06-12 Axys Pharmaceuticals, Inc. Compounds and pharmaceutical compositions as cathepsin s inhibitors
GB9928330D0 (en) * 1999-11-30 2000-01-26 Ferring Bv Novel antidiabetic agents
JP3808772B2 (ja) * 1999-12-24 2006-08-16 エフ．ホフマン−ラ ロシュ アーゲー カテプシンｋ阻害剤としてのニトリル誘導体
DE60132975T2 (de) * 2000-01-06 2009-02-26 Merck Frosst Canada Inc., Kirkland Neue substanzen und verbindungen als protease-inhibitoren
GB0003111D0 (en) * 2000-02-10 2000-03-29 Novartis Ag Organic compounds
AU2001245764A1 (en) * 2000-03-15 2001-09-24 Axys Pharmaceuticals, Inc. Novel compounds and compositions as protease inhibitors
NZ521060A (en) * 2000-03-27 2004-05-28 Applied Research Systems Pharmaceutically active pyrrolidine derivatives as bax inhibitors and method of preparation thereof
ES2262640T3 (es) * 2000-03-27 2006-12-01 Applied Research Systems Ars Holding N.V. Derivados de pirrolidina farmaceuticamente activos como inhibidores de bax.
EP1283825B1 (en) * 2000-05-15 2005-09-14 Novartis AG N-substituted peptidyl nitriles as cysteine cathepsin inhibitors
DE60139639D1 (de) * 2000-12-08 2009-10-01 Takeda Pharmaceutical Substituierte thiazolderivate mit 3-pyridylgruppen, verfahren zu deren herstellung und deren verwendung
US7030116B2 (en) * 2000-12-22 2006-04-18 Aventis Pharmaceuticals Inc. Compounds and compositions as cathepsin inhibitors
WO2002051983A2 (en) 2000-12-22 2002-07-04 Axys Pharmaceuticals, Inc. Novel compounds and compositions as cathepsin inhibitors
CA2439415C (en) 2001-03-02 2011-09-20 Merck Frosst Canada & Co. Cathepsin cysteine protease inhibitors
IL159125A0 (en) * 2001-06-01 2004-05-12 Axys Pharm Inc Novel compounds and compositions as cathepsin inhibitors
US20040147503A1 (en) * 2002-06-04 2004-07-29 Sheila Zipfeil Novel compounds and compositions as cathepsin inhibitors
WO2003024924A1 (en) * 2001-09-14 2003-03-27 Aventis Pharmaceuticals Inc. Novel compounds and compositions as cathepsin inhibitors
JP2005504827A (ja) 2001-10-02 2005-02-17 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド システインプロテアーゼの可逆性インヒビターとして有用な化合物
WO2003037892A1 (en) 2001-10-29 2003-05-08 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as reversible inhibitors of cysteine proteases
CA2465499A1 (en) * 2001-11-08 2003-05-15 Merck & Co., Inc. Compositions and methods for treating osteoporosis
EP1446115B1 (en) * 2001-11-13 2008-02-27 Merck Frosst Canada Ltd. Cyanoalkylamino derivatives as protease inhibitors
US6977256B2 (en) * 2001-11-14 2005-12-20 Aventis Pharmaceuticals Inc. Compounds and compositions as cathepsin S inhibitors
EP2316470A3 (en) 2001-11-26 2011-08-24 Trustees Of Tufts College Peptidomimetic inhibitors of post-proline cleaving enzymes
US20060009423A1 (en) * 2002-02-19 2006-01-12 Eric Joseph Niesor Phosphonate-phosphate and diphosphonate apolipoprotein e modulators
US7375134B2 (en) * 2002-03-05 2008-05-20 Axys Pharmaceuticals, Inc. Cathepsin cysteine protease inhibitors
US7087604B2 (en) 2002-03-08 2006-08-08 Bristol-Myers Squibb Company Cyclic derivatives as modulators of chemokine receptor activity
SE0201976D0 (sv) * 2002-06-24 2002-06-24 Astrazeneca Ab Novel compounds
SE0201980D0 (sv) 2002-06-24 2002-06-24 Astrazeneca Ab Novel compounds
SE0201977D0 (sv) * 2002-06-24 2002-06-24 Astrazeneca Ab Novel compounds
US7279478B2 (en) 2002-09-04 2007-10-09 Merck Frosst Canada & Co. Cathepsin cysteine protease inhibitors
EP1569954A1 (en) * 2002-12-05 2005-09-07 Axys Pharmaceuticals, Inc. Cyanomethyl derivatives as cysteine protease inhibitors
US7384970B2 (en) * 2003-03-24 2008-06-10 Irm Llc Inhibitors of cathepsin S
US7109243B2 (en) * 2003-03-24 2006-09-19 Irm Llc Inhibitors of cathepsin S
JP2006526657A (ja) * 2003-06-04 2006-11-24 アクシス ファーマシューティカルズ システインプロテアーゼ阻害剤としてのアミジノ化合物
US7173051B2 (en) * 2003-06-13 2007-02-06 Irm, Llc Inhibitors of cathepsin S
WO2005005456A2 (en) * 2003-07-08 2005-01-20 Glaxo Group Limited Peptide deformylase inhibitors
US7256207B2 (en) * 2003-08-20 2007-08-14 Irm Llc Inhibitors of cathepsin S
JP4553899B2 (ja) 2003-08-21 2010-09-29 メルク フロスト カナダ リミテツド カテプシンシステインプロテアーゼ阻害剤
US7547701B2 (en) 2003-09-18 2009-06-16 Virobay, Inc. Haloalkyl containing compounds as cysteine protease inhibitors
KR100793095B1 (ko) * 2003-10-01 2008-01-10 주식회사 프로메디텍 Ｂａｃｅ 저해효능을 가진 신규한 술폰 아미드 유도체
US7297714B2 (en) * 2003-10-21 2007-11-20 Irm Llc Inhibitors of cathepsin S
WO2005040142A1 (en) 2003-10-24 2005-05-06 Aventis Pharmaceuticals Inc. Novel keto-oxadiazole derivatives as cathepsin inhibitors
AU2004289305A1 (en) * 2003-11-10 2005-05-26 Synta Pharmaceuticals, Corp. Heteroaryl-Hydrazone compounds
WO2006042103A2 (en) * 2004-10-05 2006-04-20 Axys Pharmaceuticals, Inc. Reversible inhibitors of cathepsin b
WO2006060810A1 (en) 2004-12-02 2006-06-08 Schering Aktiengesellschaft Sulfonamide compounds as cysteine protease inhibitors
NZ555316A (en) 2004-12-09 2009-08-28 Merck & Co Inc Estrogen receptor modulators
DK1865940T3 (da) 2005-03-21 2013-03-04 Virobay Inc Alfaketoamidforbindelser som cysteinproteasehæmmere
EP1866277B1 (en) 2005-03-22 2014-06-25 Virobay, Inc. Sulfonyl containing compounds as cysteine protease inhibitors
CA2599419A1 (en) * 2005-04-22 2006-11-02 Alantos Pharmaceuticals Holding, Inc. Dipeptidyl peptidase-iv inhibitors
EP1760076A1 (en) 2005-09-02 2007-03-07 Ferring B.V. FAP Inhibitors
JP5312320B2 (ja) 2006-06-01 2013-10-09 サノフイ プロテアーゼ阻害剤としてのスピロ環式ニトリル類
US7893112B2 (en) 2006-10-04 2011-02-22 Virobay, Inc. Di-fluoro containing compounds as cysteine protease inhibitors
KR101486763B1 (ko) 2006-10-04 2015-01-28 비로베이, 인코포레이티드 시스테인 프로테아제 억제제로서의 디­플루오로 함유 화합물
JP2010513530A (ja) * 2006-12-22 2010-04-30 エンサイシブ・ファーマシューティカルズ・インコーポレイテッド Ｃ３ａ受容体の調節剤およびその使用方法
US7638541B2 (en) 2006-12-28 2009-12-29 Metabolex Inc. 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
KR20090118107A (ko) * 2007-03-08 2009-11-17 아이알엠 엘엘씨 Ｇｐｒ119 활성의 조절제로서의 화합물 및 조성물
US8183381B2 (en) 2007-07-19 2012-05-22 Metabolex Inc. N-linked heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders
EP2719700A1 (en) 2008-01-09 2014-04-16 Amura Therapeutics Limited Tetrahydrofuro(3,2-b)pyrrol-3-one derivatives as inhibitors of cysteine proteinases
EP2344480A1 (en) 2008-10-15 2011-07-20 Boehringer Ingelheim International GmbH Fused heteroaryl diamide compounds useful as mmp-13 inhibitors
EP2198879A1 (en) 2008-12-11 2010-06-23 Institut Curie CD74 modulator agent for regulating dendritic cell migration and device for studying the motility capacity of a cell
JP5518997B2 (ja) * 2009-04-20 2014-06-11 エフ．ホフマン−ラ ロシュ アーゲー カテプシン阻害薬としてのプロリン誘導体
US8324417B2 (en) 2009-08-19 2012-12-04 Virobay, Inc. Process for the preparation of (S)-2-amino-5-cyclopropyl-4,4-difluoropentanoic acid and alkyl esters and acid salts thereof
US8410127B2 (en) 2009-10-01 2013-04-02 Metabolex, Inc. Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts
AR079022A1 (es) 2009-11-02 2011-12-21 Sanofi Aventis Derivados de acido carboxilico ciclico sustituidos con acilamino, su uso como productos farmaceuticos, composicion farmaceutica y metodo de preparacion
ES2562274T3 (es) 2010-10-06 2016-03-03 Fundació Institut De Recerca Biomèdica (Irb Barcelona) Procedimiento para el diagnóstico, pronóstico y tratamiento de metástasis de cáncer de mama
SG194842A1 (en) 2011-05-16 2013-12-30 Bayer Ip Gmbh Use of cathepsin k inhibition for the treatment and/or prophylaxis of pulmonary hypertension and/or heart failure
EP2650682A1 (en) 2012-04-09 2013-10-16 Fundació Privada Institut de Recerca Biomèdica Method for the prognosis and treatment of cancer metastasis
CN104603288B (zh) 2012-06-06 2018-12-14 生物医学研究机构基金会 用于肺癌转移的诊断、预后和治疗的方法
AR091857A1 (es) * 2012-07-25 2015-03-04 Sova Pharmaceuticals Inc INHIBIDORES DE CISTATIONIN-g-LIASA (CSE)
US10119171B2 (en) 2012-10-12 2018-11-06 Inbiomotion S.L. Method for the diagnosis, prognosis and treatment of prostate cancer metastasis
KR101872965B1 (ko) 2012-10-12 2018-06-29 인바이오모션 에스.엘. Ｃ―ｍａｆ를 이용하는 전립선암 전이의 진단, 예후 및 치료 방법
US20160032399A1 (en) 2013-03-15 2016-02-04 Inbiomotion S.L. Method for the Prognosis and Treatment of Renal Cell Carcinoma Metastasis
EP2971113B1 (en) 2013-03-15 2020-08-12 Fundació Institut de Recerca Biomèdica (IRB Barcelona) Method for the prognosis and treatment of cancer metastasis
MX362041B (es) 2013-10-09 2019-01-07 Fundacio Inst De Recerca Biomedica Irb Barcelona Método para el pronóstico y tratamiento de cáncer metastásico de los huesos originado de cáncer de mama.
EA029259B1 (ru) * 2013-10-24 2018-02-28 Бристол-Маерс Сквибб Компани Ингибиторы репликации вируса иммунодефицита
DE102014116405B4 (de) * 2014-11-10 2018-10-25 Khs Gmbh Druckvorrichtung sowie Verfahren zur Bedruckung von Behältern
AU2015358868A1 (en) 2014-12-11 2017-06-01 Inbiomotion S.L. Binding members for human C-Maf
RS60048B1 (sr) 2015-02-16 2020-04-30 Univ Queensland Sulfoniluree i srodna jedinjenja i njihova upotreba
WO2017156071A1 (en) 2016-03-09 2017-09-14 Blade Therapeutics, Inc. Cyclic keto-amide compounds as calpain modulators and methods of production and use thereof
CN117230193A (zh) 2016-05-25 2023-12-15 生物运动有限公司 基于c-maf状态的乳腺癌治疗性治疗
AU2017292646A1 (en) 2016-07-05 2019-02-07 Blade Therapeutics, Inc. Calpain modulators and therapeutic uses thereof
CN109862896A (zh) 2016-08-03 2019-06-07 西玛贝医药公司 用于治疗炎症性胃肠疾病或胃肠病症的氧亚甲基芳基化合物
BR112019006110A2 (pt) * 2016-09-28 2019-09-10 Blade Therapeutics Inc moduladores de calpaína e usos terapêuticos dos mesmos
EP3649112A1 (en) 2017-07-07 2020-05-13 Inflazome Limited Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors
LT3661925T (lt) 2017-07-07 2022-03-10 Inflazome Limited Naujieji sulfonamido karboksamido junginiai
EP3668843A1 (en) 2017-08-15 2020-06-24 Inflazome Limited Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors
TW201910317A (zh) 2017-08-15 2019-03-16 愛爾蘭商英弗雷佐姆有限公司 新穎化合物
BR112020003014A2 (pt) 2017-08-15 2020-07-28 Inflazome Limited sulfonilureias e sulfoniltioureias como inibidores de vnlrp3
CA3071143A1 (en) * 2017-08-15 2019-02-21 Inflazome Limited Novel compounds
EP3707137A1 (en) 2017-11-09 2020-09-16 Inflazome Limited Novel sulfonamide carboxamide compounds
JP2021502364A (ja) 2017-11-09 2021-01-28 インフレイゾーム リミテッド 新規なスルホンアミドカルボキサミド化合物
WO2019102380A1 (en) 2017-11-22 2019-05-31 Inbiomotion S.L. Therapeutic treatment of breast cancer based on c-maf
WO2019166619A1 (en) 2018-03-02 2019-09-06 Inflazome Limited Novel compounds
KR20240035513A (ko) 2021-07-09 2024-03-15 알리고스 테라퓨틱스 인코포레이티드 항바이러스 화합물
US20240336610A1 (en) * 2021-08-02 2024-10-10 The Global Health Drug Discovery Institute 3cl protease small-molecule inhibitor for treating or preventing coronavirus infection, and use thereof
CN113563293B (zh) * 2021-08-24 2022-12-30 苏州大学 基于n-氧化物的前药复合物及其制备方法和应用
US12065428B2 (en) 2021-09-17 2024-08-20 Aligos Therapeutics, Inc. Anti-viral compounds
CN115466225B (zh) * 2022-08-16 2025-03-07 中国科学院上海药物研究所 一种酰胺类化合物及其制备方法、药物组合物和用途

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US119788A (en) * 1871-10-10 Improvement in wheels for vehicles
DE3606480A1 (de) 1986-02-28 1987-09-03 Behringwerke Ag Oligopeptidylnitrilderivate, diese enthaltende mittel, verfahren zu ihrer herstellung und ihre verwendung
JPS63301868A (ja) * 1987-06-01 1988-12-08 Nippon Kayaku Co Ltd Ｎ−（２−クロロイソニコチノイル）アミノ酸誘導体およびそれを有効成分とする農園芸用殺菌剤
DE3827415A1 (de) * 1988-08-12 1990-02-15 Behringwerke Ag Peptidderivate, verfahren zu ihrer herstellung und ihre verwendung
EP0419683A4 (en) * 1989-04-13 1992-03-11 Japan Tobacco Inc. New amino acid derivatives having prolylendopeptidase inhibitor activity
GB8909836D0 (en) 1989-04-28 1989-06-14 Boots Co Plc Therapeutic agent
ATE133407T1 (de) 1990-06-07 1996-02-15 Zeria Pharm Co Ltd Neue arylalkanoylaminderivate und diese enthaltendes arzneimittel
JPH10506091A (ja) * 1993-11-09 1998-06-16 メルク エンド カンパニー インコーポレーテッド 成長ホルモン放出促進性のピペリジン、ピロリジンおよびヘキサヒドロ−１ｈ−アゼピン類
IL111785A0 (en) 1993-12-03 1995-01-24 Ferring Bv Dp-iv inhibitors and pharmaceutical compositions containing them
JPH07228529A (ja) * 1994-02-17 1995-08-29 Zeria Pharmaceut Co Ltd コリンエステラーゼ賦活剤
ES2151055T3 (es) * 1994-03-10 2000-12-16 Searle & Co Derivados de l-n6-(1-iminoetil)lisina utiles como inhibidores de oxido nitrico sintasa.
WO1998001133A1 (fr) * 1996-07-08 1998-01-15 Yamanouchi Pharmaceutical Co., Ltd. Inhibiteurs de la resorption osseuse
DK0933379T3 (da) 1996-08-28 2006-06-26 Shionogi & Co Nye peptidderivater med thiazolyl-alanin-rest
DE69841871D1 (en) * 1997-11-05 2010-10-14 Novartis Ag Dipeptide nitrile
GB9723407D0 (en) * 1997-11-05 1998-01-07 Ciba Geigy Ag Organic compounds
US6456502B1 (en) 1998-09-21 2002-09-24 Compaq Computer Corporation Integrated circuit device/circuit board connection apparatus
GB9903861D0 (en) 1999-02-20 1999-04-14 Zeneca Ltd Chemical compounds
WO2000049007A1 (en) 1999-02-20 2000-08-24 Astrazeneca Ab Acetamido acetonitrile derivatives as inhibitors of cathepsin l and/or cathepsin s
AU2560000A (en) 1999-02-20 2000-09-04 Astrazeneca Ab Di- and tripeptide nitrile derivatives as inhibitors of cathepsin l and cathepsin
EP1159273A1 (en) * 1999-03-02 2001-12-05 Boehringer Ingelheim Pharmaceuticals Inc. Compounds useful as reversible inhibitors of cathepsin s
IL145430A0 (en) * 1999-03-15 2002-06-30 Axys Pharm Inc N-cyanomethyl amides, processes for the preparation thereof and pharmaceutical compositions containing the same
EP1159260A1 (en) * 1999-03-15 2001-12-05 Axys Pharmaceuticals, Inc. Novel compounds and compositions as protease inhibitors
ATE326454T1 (de) 1999-07-30 2006-06-15 Boehringer Ingelheim Pharma Neue bernsteinsäure derivative als cysteine- protease-inhibitoren
CN100410250C (zh) 1999-09-13 2008-08-13 贝林格尔·英格海姆药物公司 用作半胱氨酸蛋白酶的可逆抑制剂的螺旋杂环化合物
EP1212302A1 (en) * 1999-09-16 2002-06-12 Axys Pharmaceuticals, Inc. Compounds and pharmaceutical compositions as cathepsin s inhibitors
GB9925264D0 (en) 1999-10-26 1999-12-29 Zeneca Ltd Chemical compounds
HU227039B1 (en) 2000-01-25 2010-05-28 Egis Gyogyszergyar Nyilvanosan New process for the production of quetiapine and intermediates therefor
GB0003111D0 (en) 2000-02-10 2000-03-29 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
IL145429A0 (en) 2002-06-30
CZ20013217A3 (cs) 2002-04-17
HUP0200503A3 (en) 2005-06-28
US6455502B1 (en) 2002-09-24
IL145430A (en) 2006-08-01
BR0009042A (pt) 2001-12-26
AU774827B2 (en) 2004-07-08
ES2215626T3 (es) 2004-10-16
US6476026B1 (en) 2002-11-05
US20030119788A1 (en) 2003-06-26
NZ514234A (en) 2004-02-27
HUP0200347A3 (en) 2003-05-28
TR200103337T2 (tr) 2002-03-21
US20040147745A1 (en) 2004-07-29
HUP0200347A2 (en) 2002-06-29
WO2000055125A2 (en) 2000-09-21
NO20014485L (no) 2001-11-05
PL350453A1 (en) 2002-12-16
KR20010110669A (ko) 2001-12-13
EP1178958A2 (en) 2002-02-13
EA200100971A1 (ru) 2002-02-28
BG106013A (en) 2002-05-31
SK12882001A3 (sk) 2002-04-04
ZA200107494B (en) 2002-11-27
DE60008369T2 (de) 2009-10-01
EP1161415A2 (en) 2001-12-12
US6593327B2 (en) 2003-07-15
HUP0200503A2 (en) 2002-06-29
ATE299493T1 (de) 2005-07-15
AU769736B2 (en) 2004-02-05
HRP20010738B1 (en) 2005-02-28
US20030096796A1 (en) 2003-05-22
JP2002539191A (ja) 2002-11-19
EA005369B1 (ru) 2005-02-24
EE04911B1 (et) 2007-10-15
HK1044755A1 (en) 2002-11-01
AU3746100A (en) 2000-10-04
WO2000055126A2 (en) 2000-09-21
US20070015755A1 (en) 2007-01-18
HK1039108A1 (zh) 2002-04-12
EE200100485A (et) 2003-02-17
TR200103390T2 (tr) 2002-05-21
PL350456A1 (en) 2002-12-16
UA76088C2 (en) 2006-07-17
HRP20010738A2 (en) 2002-12-31
NO20014484D0 (no) 2001-09-14
IS6069A (is) 2001-09-07
HRP20010737A2 (en) 2002-10-31
CA2368148A1 (en) 2000-09-21
DE60008369D1 (en) 2004-03-25
SK12892001A3 (sk) 2002-06-04
TR200201874T2 (tr) 2002-10-21
BG106003A (en) 2002-06-28
NO20014484L (no) 2001-10-26
YU66101A (sh) 2004-07-15
WO2000055126A3 (en) 2001-02-22
BR0009043A (pt) 2002-01-08
TWI290132B (en) 2007-11-21
JP2002539192A (ja) 2002-11-19
KR100688740B1 (ko) 2007-02-28
PT1178958E (pt) 2004-07-30
ATE259782T1 (de) 2004-03-15
EP1161415B1 (en) 2005-07-13
EA200100972A1 (ru) 2002-02-28
DE60021254D1 (en) 2005-08-18
AU3748600A (en) 2000-10-04
CN1364155A (zh) 2002-08-14
CA2368122A1 (en) 2000-09-21
DK1178958T3 (da) 2004-06-21
CN1362947A (zh) 2002-08-07
WO2000055125A3 (en) 2001-04-26
US20020086996A1 (en) 2002-07-04
KR20010111277A (ko) 2001-12-17
ES2245303T3 (es) 2006-01-01
EP1178958B1 (en) 2004-02-18
DE60021254T2 (de) 2006-04-20
CZ20013248A3 (cs) 2002-04-17
IL145430A0 (en) 2002-06-30
ZA200107495B (en) 2002-09-11
EE200100487A (et) 2003-02-17

Similar Documents

Publication Publication Date Title
NO20014484D0 (no) Nye forbindelser og sammensetninger som proteaseinhibitorer
EP1248612A4 (en) NEW SUBSTANCES AND COMPOUNDS AS PROTEASE INHIBITORS
WO2000055124A3 (en) Novel compounds and compositions as protease inhibitors
NO20044731L (no) Kinolin- og isokinolinderivater fremgangsmate for fremstilling derav og anvendelse derav som betennelseshemmere
PL372809A1 (en) Substituted 1,3-diphenylprop-2-en-1-one derivatives and preparation and uses thereof
WO2001068645A3 (en) N-cyanomethylcarboxamides and their use as protease inhibitors
MXPA03005601A (es) Nuevos compuestos y composiciones como inhibidores de catepsina.
RS20060280A (en) Novel keto-oxadiazole derivatives as cathepsin inhibitors
MXPA03010766A (es) Nuevos compuestos y composiciones como inhibicores de las catepsinas.
ATE253359T1 (de) Antithrombotische mittel
MXPA04004450A (es) Nuevos compuestos y composiciones como inhibidores de catepsina s.
EP1452522A3 (en) Novel compounds and compositions as protease inhibitors
SG143979A1 (en) Novel compounds and compositions as cathepsin inhibitors

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application
FC2A Withdrawal, rejection or dismissal of laid open patent application